Cancer immunotherapeutics specialist immatics raises EUR54m


Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a pivotal Phase III study in advanced renal cell carcinoma (RCC). IMA901 is designed to induce a polyclonal antibody response by 10 different so-called tumour-associated peptides (TUMAPs) that are frequently found to be over-expressed in a large subgroup of patients with renal cell carcinoma. The company said it expects to have first results from the trial (with overall survival as primary endpoint) at the end of 2013. Immatics, which was spun-off from Tuebingen University, also said it will advance its Phase II colorectal cancer vaccine IMA910 and its preclinical project IMA950 in patients with glioblastoma. The financing round was supported by both existing and new investors. Approximately half of the funds came from dievini Hopp Biotech holding, Wellington Partners and other existing shareholders, the other half coming from new investors MIG-advised funds and AT Impf GmbH.



Luxembourg – EU environment ministers believe that the EuropeanCommission’s proposal to allow national GMO cultivation bans is incompatible with rules of the World Trade Organisation (WTO) and undermines the EU’s internal market....



Berlin - The World Health Summit is underway for its second visit to Berlin. The international conference is organised by the M8 Alliance of leading Academic Health Centers and Medical Universities and will go on until October...



Hanover - From October 5-7 the Biotechnica in Hanover attracted 9.500 visitors and 500 enterprises. This is the smallest edition for years. "In view of framework conditions currently affecting the biotech industry, this is a...



Hanover – Addex Pharmaceuticals SA, Apeiron AG and and Galapagos Genomics NV have been chosen as finalists for this year’s European BIOTECHNICA Award. From Switzerland, Austria and Belgium respectively, one of the three firms...



Most rare diseases are hereditary but their exact cause often remains unclear. Researchers at the Max Planck used Next generation sequencing to unravel the causative gene behind the rare hereditary mental retardation disorder...



Cologne/Carlsbad – Protein expression provider CEVEC Pharmaceuticals has signed a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will...



Monheim – German supplier of specialty chemicals and nutritional ingredients Cognis has launched the first milk for reducing blood cholesterol on the Chinese market. The novel food, which is enriched with natural phytosterols,...

Displaying results 81 to 90 out of 454

< Previous 81-90 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CYTOS1.10 CHF7.84%
  • WILEX3.40 EUR6.25%
  • 4SC1.28 EUR4.07%


  • BIOFRONTERA2.36 EUR-6.35%
  • FORMYCON29.79 EUR-6.35%


  • 4SC1.28 EUR52.4%
  • VITA 346.59 EUR18.7%
  • CO.DON3.11 EUR17.8%


  • MOLOGEN5.10 EUR-35.4%
  • CYTOS1.10 CHF-28.6%
  • BIOFRONTERA2.36 EUR-10.9%


  • SANTHERA100.80 CHF2511.4%
  • CYTOS1.10 CHF746.2%
  • FORMYCON29.79 EUR328.6%


  • MOLOGEN5.10 EUR-54.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.36 EUR-29.6%

No liability assumed, Date: 24.04.2015

Current issue

All issues